SCHEMBL176157

SCHEMBL176157

COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(C(C)C)ccc43)cc2)cn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 20/20 0.73
PTGS1 P23219 1/20 0.72
KDM4E B2RXH2 1/20 0.70
MEN1 O00255 1/20 0.70
PTGES O14684 1/20 0.70
USP2 O75604 1/20 0.70
TP53 P04637 1/20 0.70
CYP1A2 P05177 1/20 0.70
POLB P06746 1/20 0.70
CYP3A4 P08684 1/20 0.70
ALOX5 P09917 1/20 0.70
MAPT P10636 1/20 0.70
CYP2C9 P11712 1/20 0.70
HPGD P15428 1/20 0.70
ALOX15 P16050 1/20 0.70
MAPK1 P28482 1/20 0.70
PTGS2 P35354 1/20 0.70
MTOR P42345 1/20 0.70
RECQL P46063 1/20 0.70
RAB9A P51151 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722067 0.90 ALOX5AP (0.77) ALOX5APPTGS1
SCHEMBL1193591 0.89 ALOX5AP (0.77) ALOX5APPTGS1
SCHEMBL1193517 0.88 ALOX5AP (0.76) ALOX5APPTGS1
SCHEMBL1193425 0.87 ALOX5AP (0.79) ALOX5APPTGS1
SCHEMBL1193390 0.86 ALOX5AP (0.76) ALOX5APPTGS1
SCHEMBL167773 0.85 ALOX5AP (0.79) ALOX5APPTGS1CYP2C9
SCHEMBL170021 0.85 ALOX5AP (0.79) ALOX5APPTGS1CYP2C9
SCHEMBL1193501 0.85 ALOX5AP (0.77) ALOX5APPTGS1
SCHEMBL5530903 0.84 ALOX5AP (1.00) ALOX5APPTGS1CYP3A4ALOX5CYP2C9
SCHEMBL169014 0.84 ALOX5AP (0.69) ALOX5APPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200147064-A1 Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor AUTOIMMUNE PHARMA LLC (US) 2020-05-14 US claimed
EP-1943219-B8 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-03-07 EP claimed
EP-2404904-A1 5-lipoxygenase-activating protein (FLAP) inhibitors Amira Pharmaceuticals, Inc. (US) 2012-01-11 EP claimed
JP-4705986-B2 2011-06-22 JP claimed
EP-1943219-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2008-07-16 EP claimed
WO-2007056021-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-18 WO claimed
US-20070105866-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-10 US claimed
US-20200147064-A1 Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor AUTOIMMUNE PHARMA LLC (US) 2020-05-14 US disclosed
WO-2018152405-A1 REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR AUTOIMMUNE PHARMA LLC (US) 2018-08-23 WO disclosed
US-8710081-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2014-04-29 US disclosed
US-20140018394-A1 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AUTOIMMUNE PHARMA LLC 2014-01-16 US disclosed
US-8546431-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2013-10-01 US disclosed
US-20130102636-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors Panmira Pharmaceuticals, Inc. (US) 2013-04-25 US disclosed
US-7977359-B2 5-lipdxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2011-07-12 US disclosed
US-20110118315-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2011-05-19 US disclosed
EP-2144875-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2010-01-20 EP disclosed
US-20090192171-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2009-07-30 US disclosed
WO-2008137609-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-11-13 WO disclosed
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-20 US disclosed
US-20070105866-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105866-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885KDM4E 2621/4885
US-20110118315-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885KDM4E 2621/4885
US-20200147064-A1 Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor LTB4R, LTC4S, LTB4R2 ALOX5AP 35/4885PTGS1 22/4885KDM4E 2544/4885
US-20090192171-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885KDM4E 2621/4885
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885KDM4E 2621/4885
US-20140018394-A1 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, LTA4H, ALOX5AP ALOX5AP 3/4885PTGS1 38/4885KDM4E 2608/4885
US-20130102636-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 24/4885KDM4E 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.